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Abstract 
BACKGROUND & AIMS: Loss of the tumor suppressor Smad4 is correlated with 
progression of colorectal cancer (CRC). In mice, colon tumors expressed CCL9 and 
recruit CCR1+ myeloid cells, which facilitate tumor invasion and metastasis by secreting 
matrix metalloproteinase (MMP) 9.  
METHODS: We used human CRC cell lines to investigate the ability of Smad4 to 
regulate expression of CCL15, a human ortholog of mouse CCL9. We employed 
immunohistochemistry to compare levels of CCL15 and other proteins in 141 samples of 
human liver metastases.  
RESULTS: In human CRC cell lines, knockdown of SMAD4 increased CCL15 
expression, whereas overexpression of Smad4 decreased it. Smad4 bound directly to 
the promoter region of CCL15 gene to negatively regulate its expression; transforming 
growth factor-β (TGF-β) enhanced binding of Smad4 to the CCL15 promoter and 
transcriptional repression. In livers of nude mice, Smad4-deficinet human CRC cells 
upregulated CCL15 to recruit CCR1+ cells and promote the metastatic colonization. 
Analysis of clinical specimens showed a strong inverse correlation between levels of 
CCL15 and Smad4; metastases that expressed CCL15 contained 3-fold more CCR1+ 
cells than those without CCL15. Patients with CCL15-expressing metastases showed 
significantly shorter times of disease-free survival (DFS) than those with CCL15-negative 
metastases. CCR1+ cells in the metastases expressed the myeloid cell markers CD11b 
and myeloperoxidase, and also MMP9.  
CONCLUSIONS: In human CRC cells, loss of Smad4 leads to upregulation of CCL15 
expression. Human liver metastases with CCL15 expression contain higher numbers 
CCR1+ cells and these patients are associated with shorter DFS. Therapeutics that 
block CCL15 recruitment of CCR1+ cells may prevent metastasis of CRC to liver. 
 
Keywords: colon cancer; carcinoma; signal transduction; chemokine 
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Introduction 
    Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths 
worldwide. Although most CRC patients without metastases can be cured by surgical 
resection of the primary tumors, metastases to the liver are found in ~30% of CRC cases 
within 5 years.1 When feasible, complete surgical resection is performed for the liver 
metastases, which leads to a 5-year survival rate ranging 30–37%.2,3 Recurrence after 
resection of liver metastasis occurs in 60% of patients, within two years in most cases.4,5 
Therefore, it is imperative that we develop adjuvant drugs to prevent postoperative 
metastasis. 
    SMAD4 encodes a key molecule that mediates transforming growth factor-β 
(TGF-β) superfamily signaling, activated by TGF-β, activins, and bone morphogenetic 
proteins (BMPs). The SMAD4 gene is located in human chromosome 18q21, a region 
with frequent genetic loss of heterozygosity (LOH) in CRC.6-8 Moreover, loss of Smad4 
protein is strongly correlated with progression in the primary and metastatic CRC.9,10 The 
expression level of Smad4 is a prognostic marker in CRC. Namely, the patients whose 
CRCs express high Smad4 levels show significantly better survival than those with low 
Smad4 levels.11  
    We previously showed that in cis-Apc+/Δ716 Smad4+/– (Apc/Smad4) mice that develop 
invasive intestinal adenocarcinomas, a C-C chemokine CCL9 is secreted from the CRC 
epithelium, which recruits myeloid cells expressing its receptor CCR1.7,15 Recent studies 
in some mouse models have also revealed that bone marrow-derived cells (BMDCs) 
play critical roles in cancer invasion and metastasis.12-14 These BMDCs expressing 
markers of myeloid cell (CD11b) and granulocyte (Gr-1) create microenvironment 
suitable for cancer cell survival, invasion and metastasis through production of matrix 
metalloproteinases (MMPs), formation of the premetastatic niche and/or suppression of 
immune reactions. In cis-Apc/Smad4 mice, CCR1+ myeloid cells produce MMP9, 
allowing cancer cells to invade surrounding stromal tissues at the invasion front. In 
addition, using a mouse model of CRC liver metastasis, we have also demonstrated that 
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mouse and human CRC cell lines that secrete mouse CCL9 (mCCL9) and human CCL15 
(hCCL15; a human ortholog of mCCL9), respectively, can recruit CCR1+ myeloid cells 
around metastatic foci of the liver.16 The accumulation of CCR1+ cells is prevented by 
inhibition of the mCCL9/hCCL15–CCR1 signaling with CCR1 antagonist, knocking-down 
of mCCL9/hCCL15 gene, or introducing the CCR1 knockout mutation.15,16 Importantly, 
invasion and metastasis of the cancer cells is suppressed by preventing CCR1+ cell 
accumulation.17 Therefore, targeting the recruitment of CCR1+ myeloid cells can be an 
effective prevention strategy against CRC metastasis in the liver. However, it has not 
been investigated rigorously whether CCR1+ myeloid cells are accumulated also in 
human CRC specimens of liver metastasis. It is yet to be established whether expression 
of CCL15 has a correlation with progression of CRC. Likewise, it remains to be 
elucidated how human CRC cells express CCL15 at the molecular level. 
    Here we report that, in human clinical specimens, CCR1+ myeloid cells often 
accumulate around liver metastases of CRC that express CCL15. Importantly, patients 
with CCL15-expressing liver metastases showed significantly shorter disease-free 
survival (DFS) after curative liver resection than those with CCL15-negative metastases. 
We also show that Smad4 binds directly to the promoter region of CCL15 gene and 
negatively regulates its expression through TGF-β family signaling. In a mouse model of 
CRC liver metastasis, we demonstrate that loss of Smad4 in human CRC promotes 
expression of CCL15 to recruit CCR1+ cells and facilitates liver metastasis. Taken 
together, these results suggest that blocking the CCL15–CCR1 axis can be an 
efficacious therapeutic strategy to prevent metastatic CRC in the liver. 
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Materials and Methods 
 
Patients population 
    For the analysis of CRC liver metastases, a total of 141 liver metastases were 
obtained from 67 operations of 55 patients undergoing partial liver resection at Kyoto 
University Hospital between January 2006 and December 2010. Liver tumors were 
confirmed to be CRC liver metastases by pathological examinations. For the analysis of 
primary CRC, a total of 49 primary CRC were obtained; 27 from the patients with liver 
metastasis and 22 from stage I CRC patients without metastasis. This study protocol 
was approved by the institutional review board of Kyoto University, Kyoto, Japan, and 
patients provided their consents for the sample use and data analysis. 
 
Cell lines and reagents 
    AA/C1 cells were kindly provided from Dr. C. Paraskeva (University of Bristol).18 
HT29, Colo205, LoVo, DLD-1 and HCT116 cells were supplied from American Type 
Culture Collection. A detailed list of the antibodies used can be found in Supplementary 
Table S1. TGF-β1, BMP4 and activin-A were purchased from Peprotech, and 
LY2157299 and LDN193189 were from Wako. Trichostatin A was from SIGMA.  
 
Immunohistochemistry (IHC) analysis 
    Formalin-fixed, paraffin-embedded sections were stained with respective antibodies 
(Supplementary Table S1) by the avidin-biotin immunoperoxidase method. To quantify 
the densities of CCR1+ cells, sections were analyzed using ImageJ software. 
Measurements were recorded as the number of CCR1+ cells at the margin of liver 
metastases [5 to 8 fields (0.1mm2) analyzed per liver metastasis]. For the staining of 
Smad4 and CCL15, we interpreted a sample as positive when > 10% of the tumor cells 
were stained with the respective antibodies. 
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In vivo experimental metastasis studies 
    We injected 3.0 x 106 of cancer cells into the spleen of eight-week old female KSN 
nude mice under anesthesia. The spleen was resected 1 min after tumor injection to 
prevent splenic tumor formation that often interfered bioluminescence imaging of liver 
metastatic tumors. For in vivo bioluminescence imaging, we injected 2 mg of D-luciferin 
(VivoGlo luciferin, Promega) intraperitoneally into anesthetized tumor-bearing mice 15 
min before imaging. Bioluminescence from the luciferase-expressing tumor cells was 
scored at days 7, 14, 21 and 28 post-injection, using a Xenogen IVIS system (Xenogen 
Corporation) as previously described.16 All animal experiments were approved by the 
Animal Care and Use Committee of Kyoto University. 
 
Statistical analysis 
    All values are expressed as means ± SD. The statistical significance of differences 
was determined by Mann-Whitney U test, chi-square test or Student’s t-test. All analyses 
were two-sided, and a P value of < .05 was considered statistically significant. 
Relationships between variables were determined by Pearson’s correlation coefficients. 
Statistical analyses were performed using the SPSS software, version11.50 (SPSS Inc).
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Results 
Expression level of CCL15 is inversely correlated with that of Smad4 in human 
CRC cell lines. 
    Loss of Smad4 expression is associated with advanced stages of CRC and 
frequently observed in metastatic lesions.9,10 We previously found that colon tumors of 
Apc/Smad4-deficient mice expressed CCL9 to promote tumor invasion and metastasis.15 
Therefore, we hypothesized that expression of its human ortholog CCL15 is also 
regulated by the TGF-β family signaling through Smad4 in CRC. We first determined the 
expression levels of both Smad4 and CCL15 in human CRC cell lines. LoVo, DLD-1 and 
HCT116 have wild-type Smad4 with mutant TGF-β type II receptor (TGF-βRII),19,20 while 
HT29 and Colo205 lack Smad4 with wild-type TGF-βRII (Supplementary Table S4).21,22 
AA/C1 is a premalignant adenomatous cell line isolated from a patient with familial 
adenomatous polyposis (FAP).18 A western blot analysis showed that Smad4-deficient 
cell lines HT29 and Colo205 constitutively expressed high levels of CCL15. Among the 
Smad4-expressing cell lines, on the other hand, LoVo expressed a low level of CCL15, 
whereas DLD-1, HCT116 and adenoma AA/C1 hardly expressed it (Fig. 1A). We also 
determined the level of mRNA for CCL15 by quantitative RT-PCR, and found a high level 
in HT29, and moderate levels in Colo205 and LoVo, while very little in DLD-1 and 
HCT116, as well as in AA/C1 (Fig. 1B). We detected expression of other Smad family 
members, but their levels did not affect that of CCL15 (Fig. 1A).  
 
Smad4 negatively regulates expression of CCL15 
    To further investigate the relationship between Smad4 and CCL15 expression, we 
performed RNA interference experiments. We introduced two siRNA constructs targeting 
SMAD4 (referred as siSMAD4#1 and siSMAD4#2) into Smad4-expressing cell lines, and 
confirmed that both siSMAD4 RNA species significantly decreased expression of Smad4 
protein in these cell lines (Fig. 1C). We also confirmed that these siRNAs did not affect 
expression of other Smad members (Fig. 1C). In these Smad4-expressing cell lines, 
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Smad4 can induce luciferase from the SBE4-Luc reporter construct that contains four 
Smad-binding elements (SBEs) (Supplementary Fig. S2A). Importantly, the mRNA level 
of CCL15 was significantly increased in these cell lines when SMAD4 was 
knocked-down by siSMAD4 as determined by quantitative RT-PCR (Fig. 1D). The 
expression level of CCL15 protein was also increased after treatment with siSMAD4 
(Supplementary Fig. S1A).  
    We next investigated whether exogenous expression of Smad4 reduced the CCL15 
level in Smad4-deficient cell lines. When cMyc-tagged Smad4 was stably overexpressed 
in HT29 and Colo205 by lentiviral transduction, expression of CCL15 was significantly 
decreased in both protein and mRNA levels compared with that in the control cells (Fig. 
1E and 1F). In TGF-β signaling, ligand binding activates TGF-β receptors and 
phosphorylates Smad2/3 to form heteromeric complex with Smad4 which translocates 
into the nucleus and regulates target gene transcription.23,24 In our experiment using 
Smad4-expressing Colo205 cells, addition of TGF-β1 caused phosphorylation of Smad2 
(Supplementary Fig. S1B) and formation of the Smad2/3/4 complex (Supplementary Fig. 
S1C). Furthermore, we confirmed that the TGF-β signaling was recovered by 
transduction of Smad4 in HT29 and Colo205 cells as assessed by the SBE4-Luc 
luciferase reporter assay (Supplementary Fig. S2B). In the Smad4-expressing HT29 and 
Colo205 cells, addition of TGF-β1 further reduced CCL15 mRNA and protein levels 
compared with those in the non-treatment control (Fig. 1E and 1F). These results 
indicate that Smad4 negatively regulates CCL15 expression, whereas loss of Smad4 
promotes CCL15 expression in CRC cell lines. 
    Smad4 is one of the key transcription factors of the TGF-β superfamily signaling. Not 
only TGF-β, but also BMP and activin signaling appears to be involved in the progression 
of CRC.25 Thus, we investigated which particular signaling played major roles in CCL15 
regulation. First, we determined the endogenous expression levels of TGF-β superfamily 
ligands in CRC cell lines, and found TGF-β1 and BMP4 at significant levels 
(Supplementary Fig. S1D). We then examined Smad4-expressing HT29 and Colo205 
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cells for signal responses with TGF-β1, BMP4 and activin-A. Stimulation with 10 ng/ml of 
TGF-β1 or BMP4 suppressed CCL15 expression, while activin-A did not (Supplementary 
Fig. S1E). In LoVo cells that express Smad4 endogenously, stimulation with BMP4 
inhibited expression of CCL15, whereas TGF-β1 and activin-A had no effect 
(Supplementary Fig. S1F). As anticipated, TGF-β1 and TGF-β receptor inhibitor 
(LY2157299) phosphorylated and de-phosphorylated Smad2, respectively, in 
Smad4-expressing HT29 cells. Likewise, BMP4 and BMP receptor inhibitor 
(LDN193189) affected phosphorylation of Smad1/5/8 (Supplementary Fig. S1G). 
Furthermore, treatment with an inhibitor against either receptor increased CCL15 
expression (Supplementary Fig. S1H), indicating that both TGF-β signaling and BMP 
signaling down-regulate CCL15 expression through Smad4. 
 
Smad4 binds directly to the human CCL15 promoter and inhibits transcription 
    As shown in Fig. 1, knockdown of SMAD4 increased the expression level of CCL15, 
whereas its overexpression decreased it. Moreover, TGF-β1 and BMP4 binding to their 
cognate receptors strengthened the inhibition. Therefore, we hypothesized that the 
canonical TGF-β signaling directly inhibited transcription of CCL15 gene through Smad4. 
Sequence analysis of the promoter/enhancer region of human CCL15 gene revealed 
four SBEs (CAGAC) at positions starting –469, –424, –114 and +94 counted from the 
transcription start site (Fig. 2A, top). In addition, we found a stretch of “GCTTGGC” at the 
position starting –31, which is similar to the TGF-β–inhibitory element (TIE) reported in 
the c-Myc and Stromelysin-1 promoters (Fig. 2A, top).26–28 To test whether binding of 
Smad4 suppressed transcription from the CCL15 promoter, we performed luciferase 
reporter assays. We constructed a luciferase reporter plasmid using the –500 to +100 
region that included four SBEs and one TIE-like element (Fig. 2A, bottom). With this 
reporter, SMAD4 knockdown in Smad4-expressing cell lines caused up-regulation of the 
CCL15 promoter activity (Fig. 2B). On the other hand, Smad4 transduction into 
Smad4-deficient cell lines down-regulated the promoter activity (Fig. 2C). To these cells, 
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addition of TGF-β1 or BMP4 further reduced the CCL15 promoter activity compared with 
that in the non-treatment control, while both inhibitors up-regulated it (Fig. 2C; 
Supplementary Fig. S2C and S2D).  
    To determine which element of four SBEs or TIE is critical in CCL15 regulation, we 
used a series of deletion constructs of the CCL15 promoter that lacked the respective 
SBE or TIE, followed by the luciferase gene (Fig 2D left). When transfected with the 
constructs that carried deletion of the 3rd SBE (Δ3rd SBE) and TIE (ΔTIE), luciferase 
activities were significantly up-regulated compared with that of wild-type CCL15-Luc 
reporter transfection, indicating that the 3rd SBE and TIE are critical for the negative 
regulation of CCL15 expression (Fig 2D middle and right). 
    To test whether Smad4 binds directly to SBEs and/or TIE in the CCL15 promoter, 
we performed ChIP-PCR assays using an anti-Smad4 antibody. A quantitative PCR 
analysis of the Smad4-immunoprecipitates showed significant enrichment of the 3rd SBE 
and TIE region compared with that in the control (Fig. 2E and Supplementary Fig. S2E). 
We also evaluated the effects of TGF-β1 stimulation on the Smad4-binding to CCL15 
promoter using Smad4-expressing HT29 cells. Addition of TGF-β1 significantly 
increased the recruitment of Smad4 to the 2nd and 3rd SBEs and TIE region of the CCL15 
promoter (Fig. 2F). Collectively, these results demonstrate that Smad4 binds directly to 
the CCL15 promoter and inhibits its transcription in CRC cell lines. 
 
Smad4-deficient CRC cells recruit CCR1+ cells through the CCL15–CCR1 
signaling to promote liver metastasis in a mouse model 
    To investigate whether CCL15 expression by human CRC cells promotes their 
metastasis to the liver in transplanted mice, we injected luciferase-expressing CRC cells 
into spleens of nude mice, which enabled monitoring of the disseminated and 
metastasized tumor cells in the liver by bioluminescence. This method is also useful to 
quantify the metastasized tumor cells by photon counts (Supplementary Fig. S3A). We 
used DLD-1, HCT116 and HT29 cells (Luc-DLD-1, Luc-HCT116 and Luc-HT29, 
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respectively) engineered with stable SMAD4-knockdown (shSMAD4) or with stable 
Smad4-overexpression (see Methods). Like the siRNA data in Fig. 1C above, both 
shSMAD4 constructs (shSMAD4#1 and shSMAD4#2) decreased Smad4 expression, 
and increased CCL15 level in Luc-DLD-1 and Luc-HCT116 cells (Fig. 3A left; Fig. 3B left 
and center), whereas Smad4 overexpression reduced CCL15 expression in Luc-HT29 
cells (Fig. 3A right and 3B right). The proliferation rates of these cells were not affected in 
any of the cell lines (Supplementary Fig. S3B). Next, we assessed these transfectant 
clones in nude mice for liver metastasis. When injected with Luc-DLD-1/HCT116 
shSMAD4 cells, their bioluminescence intensity markedly increased compared with 
those with the control (Fig. 3C left and center; Fig. S3D left and center). In contrast, mice 
with Luc-HT29 cMyc-Smad4 cells showed a significant reduction in the liver 
bioluminescence compared with those with the control (Fig. 3C right and Fig. 3D right). 
Notably, mice with Smad4-depleted cells (Luc-DLD-1/HCT116 shSMAD4 and Luc-HT29 
cMyc-tag) showed substantially shorter survival than those with Smad4-expressing cells 
(Luc-DLD-1/HCT116 scramble or Luc-HT29 cMyc-Smad4) (Supplementary Fig. S3C).  
    We next histologically examined the mouse livers containing metastatic CRC cells. 
Liver tumors of Smad4-deficient cells (Luc-DLD-1/HCT116 shSMAD4 and Luc-HT29 
cMyc-tag) expressed CCL15, whereas those with Smad4-expressing cells 
(Luc-DLD-1/HCT116 scramble and Luc-HT29 cMyc-Smad4) did not (Fig. 3E). 
Consistently, Smad4-deficient tumor cells contained CCR1+ cells and MMP9+ cells 
around the liver metastases, whereas Smad4-expressing tumor cells did not (Fig. 3E). 
These results indicate that loss of Smad4 in CRC cells promotes CCL15 expression to 
recruit CCR1+ cells in the liver, which causes metastatic colonization of tumor cells 
disseminated to the mouse liver. 
 
Expression level of CCL15 is inversely correlated with that of Smad4 in human 
liver metastases of CRC 
    We previously reported that the expression level of CCL9 was increased in intestinal 
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adenocarcinomas of cis-Apc/Smad4 mice.15 As shown in Fig.1–3, we have found that 
Smad4 negatively regulates expression of CCL15 in human CRC cell lines, and that loss 
of Smad4 promotes liver metastasis of CRC through CCL15–CCR1 signaling in a mouse 
model. Therefore, we next examined clinical specimens of human CRC liver metastases 
by immunohistochemistry (IHC), and investigated whether the CCL15 level was elevated 
(Fig. 4A). Of 141 liver metastases obtained from 67 operations of 55 CRC patients 
(Table 1), we found that 63% (89 of 141) was negative for Smad4, whereas 37% (52 of 
141) was positive, which was consistent with the frequency previously reported in 
advanced stage CRC.9-11 Expression of CCL15 was found in 79% (70 of 89) of the 
Smad4-negative metastases, whereas it was in 37% (19 of 52) of the Smad4-positive 
metastases, with a significant inverse correlation between Smad4 and CCL15 
expression (odds ratio, 0.16; P < 0.01, Table 2). To evaluate the clinical significance of 
the CCL15 expression in CRC, we analyzed the disease-free survival (DFS) for the 44 
patients who underwent curative liver resection without metastasis to any other organs 
such as lungs. Statistical analysis by the log-rank test showed that the patients with 
CCL15-expressing liver metastases had a significantly shorter DFS than those with 
CCL15-negative metastases (P = 0.04, Fig.4B). In these 44 patients, the number of liver 
metastases was higher in the CCL15-positive lesions than in the CCL15-negative ones, 
although the difference was not statistically significant (P = 0.09, Supplementary Table 
S5). On the other hand, there was no substantial difference in other factors such as 
preoperative CEA levels and primary tumor size (Supplementary Table S5). 31 patients 
experienced recurrence after curative liver resection, most of which occurred in the liver 
(84%; 26 in 31 patients). 
    Taken together, we conclude that loss of Smad4 in CRC is associated with 
expression of CCL15 and poorer prognosis in human CRC as in mouse models. 
 
CCL15 recruits CCR1+ myeloid cells to metastatic microenvironment of human 
liver 
                                                  Itatani et al. 
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    Using mouse models, we previously reported that CCR1+ myeloid cells expressing 
MMP9 accumulated around the primary and metastatic CRC lesions that secreted CCL9, 
which promoted cancer invasion and metastasis to the liver.15,16 To confirm the clinical 
relevance of these findings, we performed further IHC. Notably, significant numbers of 
CCR1+ cells accumulated around the CCL15-expressing CRC cells in the liver, but few 
around the CCL15-negative cells (Fig. 4A). We quantified the density of CCR1+ cells at 
the periphery of liver metastases (Supplementary Fig. S4A), and found ~3 times more 
CCR1+ cells around the CCL15-positive metastases than around CCL15-negative ones 
(34.3 ± 18.6 vs. 10.3 ± 8.8, respectively; P < 0.01, Table 2; Fig. 4C). We also found that 
the CCR1+ cell density was inversely correlated with the metastatic tumor size (P < 0.01, 
Fig. 4D). Namely, the smaller the liver metastases, the higher numbers of CCR1+ cells 
were found around the tumors, which is similar to the observation in a mouse model.16 
To characterize the CCR1+ cells, we determined their expression of CD11b, 
myeloperoxidase (MPO), MMP9 and CD34 by immunofluorescence staining (Fig. 5). 
Because Gr-1 is not expressed in humans, we employed CD11b and MPO as human 
myeloid cell markers.29 We found that the CCR1+ cells were positive for both CD11b and 
MPO (Fig. 5A, 5B and 5C), suggesting that they are of the myeloid origin. Moreover, 
these CCR1+ myeloid cells also expressed MMP9 (Fig. 5A and 5D), which is consistent 
with the data obtained from the mouse models. Although CCR1+ myeloid cells were 
positive for CD34 in mouse models, co-staining with CCR1 and CD34 on human 
samples revealed that CCR1+ cells were negative for CD34 (Fig. 5E). This discrepancy 
among these results could be due to the difference of developmental stages of myeloid 
progenitor cells between the human and mouse.30 To understand the chronology of CRC 
metastasis, we investigated 49 primary CRC, and found that CCL15 expression within 
the primary CRC was correlated with lack of Smad4 expression, CCR1+ cell 
accumulation and liver metastasis (Supplementary Fig. S4B and Supplementary Table 
S6). These data strongly suggested that recruitment of CCR1+ cells by CCL15 is a 
feature of a human CRC subset, as well as in mice. 
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    Taken together, these results indicate that loss of Smad4 promotes expression of 
CCL15 in metastatic CRC cells to recruit CCR1+ myeloid cells, which can facilitate early 
metastatic expansion in humans as in the mouse model (Fig. 5F).
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Discussion 
    SMAD4 is one of the genes in human chromosome 18q21 where frequent LOH is 
observed in CRC progression as a well-known poor prognostic marker.9,11,31 Although 
loss of Smad4 is implicated in the progression of CRC,6–8 the molecular mechanisms 
remain to be elucidated. Here we have shown that loss of Smad4 increases expression 
of CCL15 in human CRC and causes tumor-stromal interaction through the 
CCL15–CCR1 signaling (Fig. 5F). There is an inverse correlation between the levels of 
Smad4 and CCL15 in both human CRC cell lines and clinical specimens. We have 
further confirmed that Smad4 binds directly to the promoter region of CCL15 gene to 
negatively regulate its expression through the TGF-β and BMP signaling. In the TGF-β 
family signaling, several transcriptional co-repressors recruit histone deacetylases 
(HDACs) to the Smad complexes, which leads to transcriptional repression of the target 
genes.32 We have found that Smad4 binds to HDAC4/5, and that a HDAC inhibitor, 
Trichostatin A, promotes CCL15 expression in CRC cell lines (Supplementary Fig. S2F 
and S2G). Analysis of human clinical specimens showed that CCL15-expressing CRC, 
most of which lacked Smad4 expression, contained higher density of CCR1+ myeloid 
cells in the primary tumors and liver metastases, as observed in a mouse model.15,16 
Interestingly, the smaller the liver metastases, the more CCR1+ cells accumulated 
around tumors, suggesting that CCR1+ myeloid cells help CRC cells to colonize liver 
metastasis at early stages. Recently, it has been reported that BMPs, members of the 
TGF-β superfamily, directly regulate CCL9 expression through Smad1/5/8 in mouse 
mammary tumors.33 We have also found that expression of CCL15 was decreased with 
BMP4 stimulation in human CRC cell lines (Supplementary Fig. S1E and S1F).  
    In addition to the cell-autonomous changes in cancer cells, there is mounting 
evidence that the stromal cells, e.g. BMDCs, play key roles in malignant progression.34,35 
It has been reported that hematopoietic progenitors that express CD11b and vascular 
endothelial growth factor receptor 1 (VEGFR1) accumulate at the premetastatic niche in 
lungs.12 It has been also reported that VEGFR1 and CXCR4 independently exert a 
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promigratory effect in BMDC through the VEGF/VEGFR1 and CXCL12/CXCR4 
pathways, respectively, in mouse models.36 We previously reported that CCR1+ myeloid 
cells accumulated around the primary and metastatic lesions of CRC through the 
mCCL9/hCCL15–CCR1 signaling in mouse models.15,16 Likewise, it was reported in a 
breast cancer mouse model that loss of TGF-β signaling increased CXCL1 and CXCL5 
secretion, which increased migration of CD11b+Gr-1+ myeloid-derived suppressor cells 
(MDSCs) to the tumor tissues,13 and played indirect roles in increasing the number of 
Th17 cells that have a protumorigenic effect.37 Taken together, different subsets of 
BMDCs may be involved in the invasion and metastasis of a variety of tumors through 
different chemokines. However, most these findings were obtained from mouse models, 
and it has remained to be investigated whether similar mechanisms are actually involved 
in humans. In this study, we have demonstrated that significantly larger numbers of 
CCR1+ myeloid cells are detected in CRCs expressing CCL15 than in those not 
expressing CCL15. We have also found that the patients with CCL15-expressing liver 
metastases have shorter DFS than those with CCL15-negative tumors with a statistical 
significance. Accordingly, blocking the CCL15–CCR1 axis can be an efficacious strategy 
for CRC patients to prevent liver metastasis. Larger cohort studies using CCR1 inhibitors 
may confirm the role of CCL15–CCR1 axis in liver metastasis of CRC. 
    There are some CCR1 inhibitors already used in phase I/II clinical trials to the 
patient with arthritis,38 multiple sclerosis,39 or chronic obstructive pulmonary disease 
(COPD).40 These inhibitors have already been tested for their safety although their 
efficacies in those targeted diseases remain to be seen. So far, there has been no report 
of CCR1 inhibitors employed for an anti-cancer treatment. Using a mouse model for CRC 
liver metastasis, we previously reported that a CCR1 antagonist blocked the CCR1+ cell 
accumulation and metastatic colonization with significantly prolonged survival of the 
tumor-bearing mice.16 Therefore, selectively targeting CCR1+ myeloid cells, perhaps in 
combination with conventional chemotherapeutics, can be a novel strategy against CRC 
patients with liver metastases.  
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Legends to Figures 
Figure 1. Expression of CCL15 and Smad4 in human CRC and adenoma cell lines. 
(A) Western blot analysis showing protein expression of Smad1, Smad2/3, Smad5, 
Smad4, CCL15 and β-actin (ACTB). (B) Quantitative RT-PCR analysis showing mRNA 
levels for CCL15. (C and D) Western blot (C) and quantitative RT-PCR (D) analyses 
showing Smad4 levels in Smad4-expressing CRC cell lines. Nt and Ns indicate 
non-treatment and non-silencing scramble siRNA as controls. (E and F) Western blot (E) 
and quantitative RT-PCR (F) analyses showing expressions of CCL15 and Smad4 in 
Smad4-deficient cell lines. Cells were treated with or without 10 ng/ml TGF-β1 for 24 h 
(E) or 12 h (F). The signal band strengths of western blot for CCL15 were quantified 
using Image Lab software (Bio-Rad). Results are presented as the means ± SD of 
triplicate measurements (*P < .01. **P < .05) 
 
Figure 2. Smad4 directly binds to the CCL15 promoter and negatively regulates 
its expression through TGF-β signaling. (A) Schematic representation of the CCL15 
promoter region. The sequence of this region was obtained by sequencing genomic DNA 
of HCT116, and matches with that of database obtained from UCSC genome browser.41 
Transcription start site (black arrow) was confirmed by 5’ rapid amplification of cDNA end 
(5’RACE). (B) Luciferase reporter assay for the CCL15-Luc activity with or without 
Smad4 knockdown in Smad4-expressing cell lines. Transcription activities of the CCL15 
promoter are represented as the ratio CCL15-Luc/pGL4. (C) Luciferase reporter assay 
for the CCL15-Luc activity with or without stable Smad4 overexpression in 
Smad4-deficient cell lines in the presence or absence of TGF-β1. (D) Luciferase reporter 
assay for the CCL15-Luc deletion constructs. There are typical TATA box motif (+41) 
and downstream promoter element (DPE; GACTC starting +97) in the CCL15 promoter, 
and deletion of the 4th SBE (Δ4th SBE) extended into this DPE, which may be the reason 
why the Δ4th SBE mutant showed reduced luciferase activity.42 (w.t., wild-type). (E and F) 
ChIP-PCR analysis for enrichment of each SBE or TIE in the CCL15 promoter region 
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(HCT116 in (E) and HT29 cMyc-Smad4 with 10 ng/ml TGF-β1 stimulation in (F)). DNA 
samples were analyzed by quantitative PCR and adjusted to 10% input. Western blots 
show Smad4 with 10% inputs and immunprecipitated samples (right). Results are 
presented as the means ± SD of triplicate measurements (*P < .01, **P < .05). 
 
Figure 3. Mouse xenograft models of CRC liver metastasis. (A and B) Western blot 
(A) and quantitative RT-PCR (B) analyses of luciferase-expressing CRC cell lines where 
SMAD4 was stably knocked-down (in Smad4-expressing cells; Luc-DLD-1 and 
Luc-HCT116) or overexpressed (in Smad4-deficient cells; Luc-HT29). (C) In vivo 
bioluminescence images of mice injected with luciferase-expressing CRC cells. (D) 
Quantification of the liver metastatic lesions (photon counts) in mice injected with the 
cells described in Supplementary Fig S3A. n = 3 for each group. (E) IHC analysis of 
mouse livers with xenograft CRC cell lines. Scale bar, 100 µm. Results are presented as 
the means ± SD of triplicate measurements (*P < .01). 
 
Figure 4. Expression of CCL15 and recruitment of CCR1+ cells in the liver 
metastatic lesions of CRC patients. (A) Haematoxylin and eosin staining (H & E) and 
IHC staining for Smad4, CCL15 and CCR1 of liver specimens from metastatic CRC 
patients. Upper and lower panels show serial sections of representative Smad4-negative 
and Smad4-positive liver metastases, respectively. Scale bar, 100 µm. (B) Effects of 
CCL15 expression on DFS in patients who underwent curative liver resection without any 
other distant metastases. (Kaplan-Meier estimates) (C) Quantification of the CCR1+ cell 
density in CRC liver metastases with and without CCL15 expression (n=89 and 52, 
respectively). (*P < .01; exact Mann-Whitney U test; horizontal bands show the means). 
(D) Scatter plot of tumor size and CCR1+ cell-accumulation. The relationship was 
evaluated by the Pearson’s correlation coefficient (r; correlation coefficient).  
 
Figure 5. Characterization of CCR1+ cells in the microenvironment of CRC liver 
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metastases. (A) IHC staining for CCR1, CD11b, MPO and MMP9. Scale bar, 100 µm. 
(B–E) Immunofluorescence staining for CCR1 and CD11b (B), MPO (C), MMP9 (D), and 
CD34 (E). Scale bar, 20 µm. (F) Schematic representation of the CCL15-CCR1 axis in 
liver metastasis of CRC. In CRC cells, Smad4 inhibits the expression of CCL15 
downstream of TGF-β and BMP signaling (left). Once Smad4 is inactivated, this 
inhibition is relieved and CCL15 is expressed. Chemokine CCL15 recruits CCR1+ 
myeloid cells around metastatic CRC cells. The bone marrow-derived CCR1+ cells 
produce MMPs and facilitate tumor expansion (center and right). 
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Table 1. Patient and Tumor Characteristics (141 Metastases Obtained from 67 
Operations of 55 Patients)  
 
 
Characteristics Patients Resections 
 
Age, years 
   Mean ± SD       64.8 ± 10.9 
   Range          36–87 
 
Sex         
   Male  33 
   Female  22 
 
Location of primary tumor 
   colon 37 
   rectum 18 
 
Resection times 
   One 44 
   Two 10 
   Three  1 
 
Timing 
   Synchronous 21 
   Metachronous 46 
 
CEA 
   < 5.0 20 
   ≥ 5.0 47 
 
No. of metastases 
     1  29 
     2  20 
     3   6 
     4   7 
     5    4 
     6   1 
 
Prior chemotherapy 
     No.  39 
     Yes.  28 
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Table 2. Univariate Analysis of Liver Metastases of CRC with Factors Associated with 
CCL15 Expression   
 
      CCL15 expression 
 
 Factors  + (n = 89)     – (n = 52) P-value 
 
Maximum tumor size (φ in mm) 21.6 23.0 .69 
   ± 20.3 ± 19.1 
 
Smad4 expression    < .01 
 Positive      19 33 
 Negative      70 19 
 
CCR1+ cell count    34.3 10.3 < .01 
    ± 18.6 ± 8.8 
 
 









